Lanepitant

Lanepitant is a drug that was developed by Merck & Co for the treatment of nausea and vomiting. It acts as a neurokinin 1 receptor antagonist, blocking the action of substance P, a neurotransmitter that has been associated with nausea and vomiting.

History

Lanepitant was first developed by Merck & Co, a multinational pharmaceutical company based in the United States. The drug was designed to target the neurokinin 1 receptor, a protein found in the human body that plays a key role in the transmission of signals in the nervous system.

Mechanism of Action

Lanepitant works by blocking the action of substance P, a neurotransmitter that is involved in the transmission of pain signals in the body. By blocking the action of substance P, lanepitant can help to reduce feelings of nausea and vomiting.

Clinical Trials

Lanepitant has undergone a number of clinical trials to assess its safety and efficacy. These trials have shown that the drug is generally well tolerated and can be effective in reducing symptoms of nausea and vomiting.

Side Effects

Like all drugs, lanepitant can cause side effects. The most common side effects reported in clinical trials include dizziness, headache, and fatigue. Less common side effects include dry mouth, constipation, and abdominal pain.

See Also

• Neurokinin 1 receptor
• Substance P
• Nausea
• Vomiting

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia